TRACTISS ends rituximab hopes for Sjögren’s syndrome

GLASGOW – Rituximab is unlikely to work as a treatment for Sjögren’s syndrome, according to a sneak peak of results from a multicenter study.
The study, the Trial of Anti–B Cell Therapy in Patients...

Source: Rheumatology News - May 9, 2016 Category: Rheumatology Source Type: research